| Recruiting | OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels NCT06939751 | Inova Health Care Services | — |
| Recruiting | ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Trans NCT06982404 | Medical University of Vienna | — |
| Active Not Recruiting | TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlati NCT07316829 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs NCT06532890 | Inova Health Care Services | — |
| Completed | Immunologic Risk of Pregnancy in Women With Lung Transplantion : a National Multicentric Study NCT05689905 | Nantes University Hospital | — |
| Recruiting | Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 M NCT06676696 | Hospital Universitari Vall d'Hebron Research Institute | Phase 4 |
| Unknown | Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection NCT05913583 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Enrolling By Invitation | Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation NCT05285878 | The Methodist Hospital Research Institute | Phase 2 |
| Recruiting | MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy NCT05333367 | Centre Hospitalier Universitaire de Besancon | N/A |
| Completed | Mass Spectrometry-based Proteomics in Microvascular Inflammation Diagnosis in Kidney Transplantation. NCT04851145 | University Hospital, Bordeaux | N/A |
| Unknown | Urine Biomarker for Kidney Transplant Rejection NCT05072951 | Exosome Diagnostics, Inc. | — |
| Completed | Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantatio NCT04488094 | Asan Medical Center | Phase 2 |
| Completed | Molecular HistoMx Assessment for Kidney Transplant Rejection and Management NCT07347353 | Paris Translational Research Center for Organ Transplantation | — |
| Not Yet Recruiting | Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients NCT04164576 | University Hospital, Strasbourg, France | — |
| Unknown | The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation NCT03147157 | The First Hospital of Jilin University | N/A |
| Unknown | Regenerative Cellular Therapies, Physiology, Pathology and Developmental Biology NCT02469207 | Cambridge University Hospitals NHS Foundation Trust | — |
| Completed | A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Re NCT01147302 | Shire | Phase 2 |
| Completed | Pathogenetic Risk Factors for Corneal Graft Rejection NCT06281587 | The S.N. Fyodorov Eye Microsurgery State Institution | — |
| Withdrawn | Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation NCT01035593 | Pharming Technologies B.V. | Phase 2 |
| Completed | Montelukast in Bronchiolitis Obliterans Syndrome NCT01211509 | Universitaire Ziekenhuizen KU Leuven | Phase 4 |
| Unknown | A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejec NCT00962377 | XDx | N/A |
| Completed | Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients NCT00895583 | Pfizer | Phase 4 |
| Completed | Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation NCT00807144 | Imperial College Healthcare NHS Trust | Phase 4 |
| Unknown | Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation NCT01066689 | University Hospital, Tours | Phase 3 |
| Completed | Randomized Trial for Mixed Acute Rejection NCT00771875 | University of Cincinnati | Phase 2 |
| Unknown | Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol NCT00706680 | University Health Network, Toronto | Phase 4 |
| Completed | HLA-Identical Sibling Renal Transplant Tolerance NCT00619528 | Northwestern University | N/A |
| Completed | Study of Rituximab to Treat Chronic Renal Transplant Rejection NCT00476164 | King's College London | Phase 4 |
| Completed | Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Re NCT00369382 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Completed | A Study on a New Staining Method (C4d Staining) of Transplanted Kidney Biopsies NCT00498095 | Hospital Authority, Hong Kong | — |
| Completed | Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection NCT00300274 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine i NCT00251004 | Novartis | Phase 3 |
| Completed | Azithromycin in Bronchiolitis Obliterans Syndrome NCT01009619 | KU Leuven | Phase 4 |
| Completed | Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY NCT00761787 | XDx | — |
| Recruiting | Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants NCT00106925 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplan NCT00331162 | Wake Forest University Health Sciences | Phase 4 |
| Completed | IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplan NCT00351559 | XDx | N/A |
| Completed | Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasc NCT00097968 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Lung Allograft Rejection Gene Expression Observational (LARGO) Study NCT00751309 | XDx | — |
| Completed | Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant R NCT00266123 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Completed | A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Reje NCT00089947 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipie NCT00254709 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Completed | Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Rena NCT00273871 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplante NCT00035555 | Bristol-Myers Squibb | Phase 2 |
| Completed | Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys NCT00001984 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Completed | Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants NCT00001858 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | — |
| Completed | A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at NCT00510913 | Astellas Pharma Inc | Phase 4 |
| Completed | Analysis of a Beneficial Effect of Prolonges Topical Steroid Treatment After Low-risk Penetrating Keratoplasty NCT00450996 | University of Erlangen-Nürnberg Medical School | N/A |
| Completed | Collaborative Corneal Transplantation Studies (CCTS) NCT00000137 | National Eye Institute (NEI) | Phase 3 |
| Unknown | Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA) NCT00290069 | Sociedad Andaluza de Trasplantes de Organos y Tejidos | Phase 4 |
| Completed | Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients NCT00261820 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |